Yellow Fever - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 34 pages report, published by Global Markets Direct

Keywords : Yellow Fever Therapeutic Products under Development, Key Players in Yellow Fever Therapeutics, Yellow Fever Pipeline Overview, Yellow Fever Pipeline, Yellow Fever Pipeline Assessment

Report ThumbnailSeptember-2013
Yellow Fever - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Yellow Fever - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Yellow Fever, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Yellow Fever. Yellow Fever - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Yellow Fever.
- A review of the Yellow Fever products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Yellow Fever pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Yellow Fever.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Yellow Fever pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Yellow Fever, H2 2013 7
  • Products under Development for Yellow Fever - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Products under Investigation by Universities/Institutes, H2 2013 10
  • Late Stage Products, H2 2013 11
  • Discovery and Pre-Clinical Stage Products, H2 2013 12
  • Assessment by Monotherapy Products, H2 2013 18
  • Assessment by Route of Administration, H2 2013 19
  • Assessment by Stage and Route of Administration, H2 2013 20
  • Assessment by Molecule Type, H2 2013 21
  • Assessment by Stage and Molecule Type, H2 2013 22
  • List of Tables
  • Number of Products Under Development for Yellow Fever, H2 2013 7
  • Products under Development for Yellow Fever - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Number of Products under Investigation by Universities/Institutes, H2 2013 10
  • Comparative Analysis by Late Stage Development, H2 2013 11
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 12
  • Products under Development by Companies, H2 2013 13
  • Products under Investigation by Universities/Institutes, H2 2013 14
  • Crucell N.V., H2 2013 15
  • Panacea Biotec Limited, H2 2013 16
  • iBio, Inc., H2 2013 17
  • Assessment by Monotherapy Products, H2 2013 18
  • Assessment by Stage and Route of Administration, H2 2013 20
  • Assessment by Stage and Molecule Type, H2 2013 22
  • Yellow Fever Therapeutics - Dormant Products 30
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Yellow Fever Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Yellow Fever 7
  • Yellow Fever Therapeutics under Development by Companies 9
  • Yellow Fever Therapeutics under Investigation by Universities/Institutes 10
  • Late Stage Products 11
  • Comparative Analysis 11
  • Discovery and Pre-Clinical Stage Products 12
  • Comparative Analysis 12
  • Yellow Fever Therapeutics - Products under Development by Companies 13
  • Yellow Fever Therapeutics - Products under Investigation by Universities/Institutes 14
  • Companies Involved in Yellow Fever Therapeutics Development 15
  • Crucell N.V. 15
  • Panacea Biotec Limited 16
  • iBio, Inc. 17
  • Yellow Fever - Therapeutics Assessment 18
  • Assessment by Monotherapy Products 18
  • Assessment by Route of Administration 19
  • Assessment by Molecule Type 21
  • Drug Profiles 23
  • Flavimun - Drug Profile 23
  • Product Description 23
  • Mechanism of Action 23
  • R&D Progress 23
  • Yellow Fever Vaccine - Drug Profile 24
  • Product Description 24
  • Mechanism of Action 24
  • R&D Progress 24
  • squalamine lactate - Drug Profile 25
  • Product Description 25
  • Mechanism of Action 25
  • R&D Progress 25
  • DiTU - Drug Profile 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • BG-323 - Drug Profile 27
  • Product Description 27
  • Mechanism of Action 27
  • R&D Progress 27
  • Egg Based Viral Vaccine For Yellow Fever - Drug Profile 28
  • Product Description 28
  • Mechanism of Action 28
  • R&D Progress 28
  • Yellow Fever Vaccine - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • Yellow Fever Therapeutics - Dormant Products 30
  • Yellow Fever - Product Development Milestones 31
  • Featured News & Press Releases 31
  • Sep 19, 2011: Georgetown University Medical Center Researcher Proves Shark Compound To Be Potential Drug To Treat Human Viruses 31
  • Appendix 33
  • Methodology 33
  • Coverage 33
  • Secondary Research 33
  • Primary Research 33
  • Expert Panel Validation 33
  • Contact Us 34
  • Disclaimer 34

Please select a license type

Share

Related Products

Global Markets DirectYellow Fever - Pipeline Review, H2 2013Product ThumbnailYellow Fever - Pipeline Review, H2 2013, Industry ReportProduct #: 113316
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved